Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC

被引：0

作者：

Griesingerl, Frank ^{[1
]}

Garassino, Marina ^{[2
,3
]}

Felip, Enriqueta ^{[4
]}

Sakai, Hiroshi ^{[5
,6
]}

Le, Xiuning ^{[7
]}

Veillon, Remi ^{[8
]}

Smit, Egbert ^{[9
]}

Raskin, Jo ^{[10
]}

Thomas, Michael ^{[11
,12
,13
]}

Ahn, Myung-Ju ^{[14
]}

Lee, Matthew ^{[15
]}

Vlassak, Soetkin ^{[16
,17
]}

Bruns, Rolf ^{[18
]}

Johne, Andreas ^{[19
]}

Palle, Paul K. ^{[20
]}

机构：

[1] Carl von Ossietzky Univ Oldenburg, Dept Hematol & Oncol, Pius Hosp, Oldenburg, Germany

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA

[4] Vali Hebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[5] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan

[6] Ageo Cent Gen Hosp, Dept Thorac Oncol, Saitama, Japan

[7] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[8] CHU Bordeaux, Serv Malad Resp, Bordeaux, France

[9] Leiden Univ, Dept Pulm Dis, Med Ctr, Leiden, Netherlands

[10] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium

[11] Univ Heidelberg Hosp, Thoraxklin & Natl Ctr Tumor Dis, Heidelberg, Germany

[12] Translat Lung Res Ctr Heidelberg TLRCH, Heidelberg, Germany

[13] German Ctr Lung Res DZL, Heidelberg, Germany

[14] Sungkyunkwan Univ, Hematol Oncol Sect, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[15] EMD Serono, Rockland, MA USA

[16] Merck NS SA, Global Med Affairs, Overijse, Belgium

[17] Merck KGaA, Darmstadt, Germany

[18] Healthcare Business Merck KGaA, Dept Biostat, Darmstadt, Germany

[19] Healthcare Business Merck KGaA, Global Clin Dev, Darmstadt, Germany

[20] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PP01.83

引用

页码：E37 / E38

页数：2

共 50 条

[41] METex14 ctDNA Dynamics & Resistance Mechanisms Detected in Liquid Biopsy (LBx) From Patients (pts) With METex14 Skipping NSCLC Treated With Tepotinib
Paik, P.
O'Hara, R.
Veillon, R.
Felip, E.
Cortot, A.
Sakai, H.
Mazieres, J.
Thomas, M.
Reinmuth, N.
Raskin, J.
Conte, P.
Garassino, M.
Iams, W. T.
Griesinger, F.
Kowalski, D.
Stroh, C.
Juraeva, D.
Scheuenpflug, J.
Johne, A.
Le, X.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E13 - E14
[42] METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib.
Paik, Paul K.
Veillon, Remi
Felip, Enriqueta
Cortot, Alexis
Sakai, Hiroshi
Mazieres, Julien
Thomas, Michael
Reinmuth, Niels
Raskin, Jo
Conte, Pier Franco
Garassino, Marina Chiara
Iams, Wade Thomas
Griesinger, Frank
Kowalski, Dariusz M.
Stroh, Christopher
Juraeva, Dilafruz
Scheuenpflug, Juergen
Johne, Andreas
Le, Xiuning
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study
Sakai, Hiroshi
Veillon, Remi
Cortot, Alexis B.
Felip, Enriqueta
Mazieres, Julien
Morise, Masahiro
Sakamoto, Tomohiro
Tokito, Takaaki
Atagi, Shinji
Kato, Terufumi
Kumagai, Toru
Tanaka, Hiroshi
Bruns, Rolf
Straub, Josef
Scheele, Juergen
Le, Xiuning
Paik, Paul K.
ANNALS OF ONCOLOGY, 2019, 30
[44] Phase II study of tepotinib in NSCLC patients with METex14 mutations.
Paik, Paul K.
Veillon, Remi
Cortot, Alexis B.
Felip, Enriqueta
Sakai, Hiroshi
Mazieres, Julien
Griesinger, Frank
Horn, Leora
Senellart, Helene
Van Meerbeeck, Jan P.
de Castro Carpeno, Javier
Patel, Jyoti D.
Garassino, Marina Chiara
Morise, Masahiro
Reinmuth, Niels
Viteri, Santiago
Tokito, Takaaki
Sakamoto, Tomohiro
Scheele, Juergen
Le, Xiuning
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
Paik, Paul K.
Yang, Mo
Knowles, Emma
Hatswell, Anthony
Vioix, Helene
Liu, Frank Xiaoqing
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
[46] Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study
Paik, Paul K.
Garassino, Marina Chiara
Le, Xiuning
Thomas, Michael
Sakai, Hiroshi
Veillon, Remi
Smit, Egbert F.
Mazieres, Julien
Cortot, Alexis B.
Raskin, Jo
Viteri, Santiago
Yang, James Chih-Hsin
Ahn, Myung-Ju
Wu, Yi-Long
Zhao, Jun
Adrian, Svenja
Berghoff, Karin
Bruns, Rolf
Johne, Andreas
Felip, Enriqueta
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Veillon, Remi
Sakai, Hiroshi
Le, Xiuning
Felip, Enriqueta
Cortot, Alexis B.
Smit, Egbert F.
Park, Keunchil
Griesinger, Frank
Britschgi, Christian
Wu, Yi-Long
Melosky, Barbara
Baijal, Shobhit
de Castro Jr, Gilberto
Sedova, Michaela
Berghoff, Karin
Otto, Gordon
Paik, Paul K.
CLINICAL LUNG CANCER, 2022, 23 (04) : 320 - 332
[48] NSCLC with METex14 Skipping Mutation Targeted Therapy with Tepotinib closes therapeutic Gap
Warpakowski, Andrea
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
[49] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
Kato, Terufumi
Yang, James Chih-Hsin
Ahn, Myung-Ju
Sakai, Hiroshi
Morise, Masahiro
Chen, Yuh-Min
Han, Ji-Youn
Yang, Jin-Ji
Zhao, Jun
Hsia, Te-Chun
Berghoff, Karin
Bruns, Rolf
Vioix, Helene
Lang, Simone
Johne, Andreas
Le, Xiuning
Paik, Paul K.
BRITISH JOURNAL OF CANCER, 2024, 130 (10) : 1679 - 1686
[50] NSCLC Targeted Treatment of METex14 Skipping Gene Mutation
Freye, Reimund
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)

← 1 2 3 4 5 →